Sarpogrelate has been investigated for the treatment of Diabetes Mellitus, Diabetic Nephropathy, Coronary Artery Disease, and Renal Insufficiency, Chronic.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Apixaban. |
| Dasatinib | Dasatinib may increase the anticoagulant activities of Sarpogrelate. |
| Ursodeoxycholic acid | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Hyodeoxycholic Acid. |
| Glucosamine | Glucosamine may increase the antiplatelet activities of Sarpogrelate. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Ibritumomab tiuxetan. |
| Ibrutinib | The risk or severity of adverse effects can be increased when Ibrutinib is combined with Sarpogrelate. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Obinutuzumab. |
| Pentoxifylline | Pentoxifylline may increase the antiplatelet activities of Sarpogrelate. |
| Rivaroxaban | Sarpogrelate may increase the anticoagulant activities of Rivaroxaban. |
| Tipranavir | Tipranavir may increase the antiplatelet activities of Sarpogrelate. |
| Urokinase | Sarpogrelate may increase the anticoagulant activities of Urokinase. |
| Vitamin E | Vitamin E may increase the antiplatelet activities of Sarpogrelate. |
| Buprenorphine | Sarpogrelate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sarpogrelate. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Sarpogrelate. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Sarpogrelate. |
| Hydrocodone | Sarpogrelate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sarpogrelate. |
| Magnesium sulfate | The therapeutic efficacy of Sarpogrelate can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Sarpogrelate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Sarpogrelate may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sarpogrelate. |
| Mirtazapine | Sarpogrelate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Sarpogrelate. |
| Orphenadrine | Sarpogrelate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Sarpogrelate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Sarpogrelate. |
| Pramipexole | Sarpogrelate may increase the sedative activities of Pramipexole. |
| Ropinirole | Sarpogrelate may increase the sedative activities of Ropinirole. |
| Rotigotine | Sarpogrelate may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Sarpogrelate. |
| Sodium oxybate | Sarpogrelate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Sarpogrelate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sarpogrelate. |
| Thalidomide | Sarpogrelate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Sarpogrelate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Sarpogrelate. |
| Pentosan polysulfate | The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Sarpogrelate. |
| Limaprost | Limaprost may increase the antiplatelet activities of Sarpogrelate. |
| Omega-3 fatty acids | Omega-3 fatty acids may increase the antiplatelet activities of Sarpogrelate. |
| Tositumomab | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Tositumomab. |
| Ethanol | Sarpogrelate may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Sarpogrelate may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Sarpogrelate. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Fluvoxamine. |
| Citalopram | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Paroxetine. |
| Sibutramine | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Nefazodone. |
| Zimelidine | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of bleeding can be increased when Desvenlafaxine is combined with Sarpogrelate. |
| Seproxetine | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Alaproclate. |
| Zopiclone | The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Zopiclone. |
| Lepirudin | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Lepirudin. |
| Bivalirudin | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Bivalirudin. |
| Alteplase | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Alteplase. |
| Reteplase | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Reteplase. |
| Anistreplase | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Anistreplase. |
| Tenecteplase | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Tenecteplase. |
| Abciximab | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Abciximab. |
| Drotrecogin alfa | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Drotrecogin alfa. |
| Streptokinase | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Streptokinase. |
| Dicoumarol | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Dicoumarol. |
| Argatroban | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Argatroban. |
| Ardeparin | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Ardeparin. |
| Phenindione | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Phenindione. |
| Fondaparinux | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Fondaparinux. |
| Warfarin | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Warfarin. |
| Phenprocoumon | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Phenprocoumon. |
| Dipyridamole | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Dipyridamole. |
| Heparin | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Heparin. |
| Enoxaparin | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Enoxaparin. |
| Epoprostenol | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Epoprostenol. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of bleeding can be increased when Sarpogrelate is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Coumarin. |
| Ximelagatran | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Ximelagatran. |
| Desmoteplase | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Desmoteplase. |
| Defibrotide | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Defibrotide. |
| Ancrod | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Ancrod. |
| Beraprost | The risk or severity of bleeding can be increased when Sarpogrelate is combined with Beraprost. |